Application of probiotics in candidiasis management

Andrade, José Carlos; Kumar, Sunil; Kumar, Awanish; Černáková, Lucia; Rodrigues, Célia Fortuna

doi:10.1080/10408398.2021.1926905

Cited by 24 publications

(17 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Later, in 1838, the infection was first described as directly linked specifically to Candida albicans , by pediatrician Francois Veilleux [ 7 ]. However, recently, non- Candida albicans Candida species (NCACs), such as Candida glabrata, Candida tropicalis , and Candida krusei have been highly related to these infections [ 8 , 9 ], colonizing mostly (but not only) older patients [ 10 ]. Oral candidiasis is diagnosed through differential patterns of mucosal changes (e.g., erythematous, pseudomembranous, and curd-like plaques—biofilms) [ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates from a Hospital in Slovakia

et al. 2022

Self Cite

View full text Add to dashboard Cite

Oral fungal infections are a worldwide healthcare problem. Although Candida albicans is still the most common yeast involved in the infections of oral cavity, non-Candida albicans Candida species (NCACs) have been highly related to these infections, particularly in older, immunosuppressed or patients with long exposure to antimicrobial drugs. The goal of this work was to perform a quick epidemiological and mycological study on the oral samples collected from a laboratory of a hospital in Slovakia, for 60 days. The samples’ identification was performed by Germ-tube formation test, CHROMID® Candida, Auxacolor 2, ID 32C automated method, and the antifungal susceptibility testing determined by E-test®. Results confirm that comparing with bacteria, yeasts still occur in the lower number, but there is a high rate of antifungal resistance (81.6%)—to, at least one drug—among the collected samples, particularly to azoles and 5′-FC, which is clinically noteworthy.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates from a Hospital in Slovakia

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The etiology of periodontal disease is associated with bacterial plaque and considers three important factors that will determine whether the disease develops; these factors are: a susceptible host, the presence of pathogenic species, and the reduction or absence of beneficial bacteria [ 3 ]. Additionally, the role of other microorganisms should be highlighted, such as fungal species, which may act as a cofactor inducing the production of pro-inflammatory cytokines and favoring the occurrence of periodontal attachment loss [ 4 , 5 ]. Epidemiological studies show that periodontal disease and gingivitis represent a serious public health problem that can lead to systemic diseases such as diabetes and cardiovascular diseases.…”

Section: Introductionmentioning

confidence: 99%

The Use of Probiotics as Adjuvant Therapy of Periodontal Treatment: A Systematic Review and Meta-Analysis of Clinical Trials

et al. 2022

View full text Add to dashboard Cite

For many years, the use of probiotics in periodontitis treatment was reflected in their abilities to control the immune response of the host to the presence of pathogenic microorganisms and to upset periodontopathogens. Accordingly, the aim of the present study was to assess the use of probiotics as adjuvant therapy on clinical periodontal parameters throughout a systematic review and meta-analysis. The literature was screened, up to 4 June 2021, by two independent reviewers (L.H. and R.B.) in four electronic databases: PubMed (MedLine), ISI Web of Science, Scielo, and Scopus. Only clinical trials that report the effect of the use of probiotics as adjuvants in the treatment of periodontal disease were included. Comparisons were carried out using Review Manager Software version 5.3.5 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). A total of 21 studies were considered for the meta-analysis. For the index plaque, the use of probiotics did not improve this clinical parameter (p = 0.16). On the other hand, for the periodontal pocket depth, the clinical attachment loss, the bleeding on probing, and the use of probiotics as adjuvant therapy resulted in an improvement of these parameters, since the control group achieved statistically higher values of this parameter (p < 0.001; p < 0.001; and p = 0.005, respectively). This study suggests that the use of probiotics led to an improvement in periodontal pocket depth, clinical attachment loss, and bleeding on probing parameters. On the other hand, this protocol seems to not be beneficial for the index plaque parameter.

show abstract

“…However, in the last decade, the non- Candida albicans Candida species (NCACs) (e.g., Candida glabrata , Candida krusei , Candida tropicalis , or Candida parapsilosis ) have been escalating due to the widespread use and even overuse of broad-spectrum antimicrobial drugs. In addition, and more alarmingly, NCACs have been linked to high rates of antifungal resistance and chronic infections [ 1 , 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Marine Compounds with Anti-Candida sp. Activity: A Promised “Land” for New Antifungals

Alves

Cruz‐Martins

Rodrigues

2022

JoF

Self Cite

View full text Add to dashboard Cite

Candida albicans is still the major yeast causing human fungal infections. Nevertheless, in the last decades, non-Candida albicans Candida species (NCACs) (e.g., Candida glabrata, Candida tropicalis, and Candida parapsilosis) have been increasingly linked to Candida sp. infections, mainly in immunocompromised and hospitalized patients. The escalade of antifungal resistance among Candida sp. demands broadly effective and cost-efficient therapeutic strategies to treat candidiasis. Marine environments have shown to be a rich source of a plethora of natural compounds with substantial antimicrobial bioactivities, even against resistant pathogens, such as Candida sp. This short review intends to briefly summarize the most recent marine compounds that have evidenced anti-Candida sp. activity. Here, we show that the number of compounds discovered in the last years with antifungal activity is growing. These drugs have a good potential to be used for the treatment of candidiasis, but disappointedly the reports have devoted a high focus on C. albicans, neglecting the NCACs, highlighting the need to perform outspreading studies in the near future.

show abstract

Application of probiotics in candidiasis management

Cited by 24 publications

References 146 publications

Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates from a Hospital in Slovakia

Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates from a Hospital in Slovakia

The Use of Probiotics as Adjuvant Therapy of Periodontal Treatment: A Systematic Review and Meta-Analysis of Clinical Trials

Marine Compounds with Anti-Candida sp. Activity: A Promised “Land” for New Antifungals

Contact Info

Product

Resources

About